FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different CLOSED - 12/NW/0014 Regimens of Mipomersen in 6 22/11/2013 NO In Follow-up Patients with Familial Hypercholesterolemia and Inadequately Controlled (MIP038) ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed CLOSED - 10/H0718/93 7 30/08/2013 NO Peripheral T-cell Lymphoma Who In Follow-up Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy ALTERNATIVE. Comparing safety & efficacy of 11/LO/1619 5 02/01/2015 CLOSED NO AI/lapatanib/trastuzumab in HR+HER2 MBC
12/NW/0014 FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled (MIP038) 6 22/11/2013 CLOSED - In Follow-up NO 10/H0718/93 ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy 7 30/08/2013 CLOSED - In Follow-up NO 11/LO/1619 ALTERNATIVE. Comparing safety & efficacy of AI/lapatanib/trastuzumab in HR+HER2 MBC 5 02/01/2015 CLOSED NO
PID-Q12015-16.docx